March 01, 2015

Boehringer Ingelheim launches SOURCE for PED management information

6-step protocol & website resource center helps producers manage PED virus

To provide pork producers and veterinarians the practical management protocols and a comprehensive information resource to help them achieve more effective prevention and control of porcine epidemic diarrhea (PED) virus, Boehringer Ingelheim Vetmedica, Inc. (BIVI), introduces SOURCE. 

According to Greg Cline, DVM, technical manager for enteric disease products at BIVI, SOURCE is a six-step systematic approach to PED prevention and control featuring one of the industry’s most complete information resources on PED. It was developed based on the company’s decades of experience and extensive research with other highly infectious swine diseases.

“SOURCE is a logical, science-based approach to PED control and management. This approach and its principles have proven highly effective in helping the industry manage other costly swine diseases,” Cline says.

“We’ve taken proven concepts and the benefits of a holistic approach to analyzing disease goals, risk and management, and added much of what we’ve recently learned about PED, to develop sound, practical management protocols that producers can implement into their specific operations.”

SOURCE is an acronym, with each letter representing one of six steps in the protocol: State desired goals; Obtain current status; Understand current risk factors; Reduce risk factors; Construct solutions; and Execute and monitor solutions.

“The first step – state desired goals – is often overlooked and probably the most important protocol as it ultimately impacts all the other steps in the process,” Cline explains. “It helps producers answer critical questions, for example, do you want to eliminate the virus? Do you want to diminish the effects of the virus? Or do you want to prevent the virus from entering the herd?"

Each step of SOURCE helps producers to objectively evaluate all components of their production systems, assess various risk factors and, based on that information, develop and execute proper management solutions that best fit their farm goals.

SOURCE also is a consolidated information resource that utilizes BIVI’s extensive swine technical and diagnostic expertise. The site includes links to additional university and industry sites and an interactive risk analysis and herd management plan. Because the site is an always-evolving information platform, any new PED data and information will be shared as it becomes available. The company has plans to expand SOURCE later this year to include expanded risk analysis and links to additional resources.

“No other animal health company brings together the breadth of technical information, field-applicable research and management protocols in a single program to help producers and veterinarians better manage PED,” Cline adds. “We’re confident SOURCE will serve as a valuable resource for producers and veterinarians dealing with PED.”

Information on PED SOURCE can be found at

About Boehringer Ingelheim Vetmedica, Inc.

Boehringer Ingelheim Vetmedica, Inc., (BIVI) is a leader in the animal health industry with its portfolio of innovative vaccine and pharmaceutical solutions for the prevention and treatment of disease within the swine, cattle, equine and pet markets.  BIVI is the U.S. division of the global Boehringer Ingelheim Animal Health GmbH.  Our U.S. headquarters are located within the KC Animal Health Corridor in St. Joseph, Mo., with other sites in Ames, Fort Dodge and Sioux Center, Iowa.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates and more than 47,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim’s culture. Involvement in social projects, caring for the employees and their families and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors of all Boehringer Ingelheim’s endeavors.

With nearly 3,000 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about $1.46 billion (1.07 billion euros) in 2013. In our research-driven Animal Health business, Boehringer Ingelheim continually invests more than 10% of net sales of the Animal Health business in R&D.

For more information please visit

Contact Information

  • Boehringer Ingelheim Vetmedica, Inc.

    Swine Division

    3902 Gene Field Road
    St. Joseph, Missouri 64506

    • Phone 866-638-2226
    • Fax 816-676-4754
    • e-mail